|Synonyms||MEDI9929, AMG 157|
|Chemical and physical data|
|Molar mass||144.6 kDa|
Tezepelumab (MEDI9929, AMG 157) (INN) is a human monoclonal antibody designed for the treatment of asthma and atopic dermatitis. It blocks Thymic stromal lymphopoietin (TSLP), an epithelial cytokine that has been suggested to be critical in the initiation and persistence of airway inflammation .
It is currently at Phase III trials.
- Statement On A Nonproprietary Name Adopted By The USAN Council - Tezepelumab, American Medical Association.
- World Health Organization (2015). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 113" (PDF). WHO Drug Information. 29 (2).
- Tezepelumab granted Breakthrough Therapy Designation by US FDA - AstraZeneca Press Release
|This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it.|